Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
71 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Pipeline Review, H2 2016', provides in depth analysis on Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted pipeline therapeutics. The report provides comprehensive information on the Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - The report reviews Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics and enlists all their major and minor projects - The report assesses Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) Overview 9 Therapeutics Development 10 Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Products under Development by Stage of Development 10 Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Products under Development by Therapy Area 11 Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Products under Development by Indication 12 Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Pipeline Products Glance 13 Late Stage Products 13 Early Stage Products 14 Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Products under Development by Companies 15 Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Products under Development by Universities/Institutes 17 Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Therapeutics Assessment 19 Assessment by Monotherapy/Combination Products 19 Assessment by Mechanism of Action 20 Assessment by Route of Administration 21 Assessment by Molecule Type 22 Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Companies Involved in Therapeutics Development 23 Actinogen Limited 23 Ahn-Gook Pharmaceutical Co., Ltd. 24 Astellas Pharma Inc. 25 AstraZeneca Plc 26 Connexios Life Sciences Pvt. Ltd. 27 F. Hoffmann-La Roche Ltd. 28 Hyundai Pharmaceutical Co., Ltd. 29 Merck & Co., Inc. 30 Pfizer Inc. 31 Poxel SA 32 Sanofi 33 Shanghai Pharmaceutical Co., Ltd. 34 SK Chemicals Co., Ltd. 35 Sumitomo Dainippon Pharma Co., Ltd. 36 Toray Industries, Inc. 37 Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Drug Profiles 38 ASP-3662 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 AZD-4017 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 BI-135558 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 CNX-1049 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Drug to Inhibit 11Beta-HSD1 for Hypertension - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Drugs to Inhibit 11beta-HSD1 for Wound Healing - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 DSP-0011 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 HIS-388 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 HOB-046 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 HSD-621 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 KR-66344 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 NCE-402 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 RG-4929 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 RO-5093151 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 SAR-184841 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 Small Molecules to Inhibit 11 Beta Hydroxysteroid Dehydrogenase 1 for Metabolic Diseases - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 Small Molecules to Inhibit 11 Beta Hydroxysteroid Dehydrogenase 1 for Metabolic Diseases - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 Small Molecules to Inhibit 11 Beta-Hydroxysteroid Dehydrogenase 1 for Type 2 Diabetes - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 UAI-101 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 UE-2343 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Dormant Projects 60 Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Discontinued Products 62 Corticosteroid 11 Beta Dehydrogenase Isozyme 1 (11 Beta Hydroxysteroid Dehydrogenase 1 or Short Chain Dehydrogenase/Reductase Family 26C Member 1 or HSD11B1 or EC 1.1.1.146) - Featured News & Press Releases 63 Sep 29, 2016: FDA Feedback On Xanamem Alzheimers Trial 63 Jul 27, 2016: Actinogen Medical Announces Landmark Research on Excess Cortisol and Alzheimer's Disease 63 Jul 20, 2016: US Patent Granted - Further Extends Xanamem Protection 64 Mar 22, 2016: XanADu: A New Pivotal Global Clinical Trial to Treat Mild Alzheimer's Disease 64 Sep 29, 2015: Positive Trial Results for Alzheimers Drug Xanamem 65 Aug 11, 2015: Clinical Trial Successfully Completed With Xanamem-AN Alzheimers Drug 66 Jun 11, 2015: Excellent Research Progress With Xanamem - A Promising Alzheimers Drug 67 Apr 13, 2015: EU Patent Granted - Further Extends Xanamem Protection 68 Jun 05, 2013: Enzyme Could Be The Key To Aiding Wound Healing In Diabetic And Elderly People 69 Appendix 70 Methodology 70 Coverage 70 Secondary Research 70 Primary Research 70 Expert Panel Validation 70 Contact Us 70 Disclaimer 71
List of Tables
Number of Products under Development for, H2 2016 10 Number of Products under Development by Therapy Area, H2 2016 11 Number of Products under Development by Indication, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Early Stage Products, H2 2016 14 Number of Products under Development by Companies, H2 2016 15 Products under Development by Companies, H2 2016 16 Number of Products under Investigation by Universities/Institutes, H2 2016 17 Products under Investigation by Universities/Institutes, H2 2016 18 Assessment by Monotherapy/Combination Products, H2 2016 19 Number of Products by Stage and Mechanism of Action, H2 2016 20 Number of Products by Stage and Route of Administration, H2 2016 21 Number of Products by Stage and Molecule Type, H2 2016 22 Pipeline by Actinogen Limited, H2 2016 23 Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H2 2016 24 Pipeline by Astellas Pharma Inc., H2 2016 25 Pipeline by AstraZeneca Plc, H2 2016 26 Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016 27 Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 28 Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 29 Pipeline by Merck & Co., Inc., H2 2016 30 Pipeline by Pfizer Inc., H2 2016 31 Pipeline by Poxel SA, H2 2016 32 Pipeline by Sanofi, H2 2016 33 Pipeline by Shanghai Pharmaceutical Co., Ltd., H2 2016 34 Pipeline by SK Chemicals Co., Ltd., H2 2016 35 Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 36 Pipeline by Toray Industries, Inc., H2 2016 37 Dormant Projects, H2 2016 60 Dormant Projects (Contd..1), H2 2016 61 Discontinued Products, H2 2016 62
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
